UK-based PolyPhotonix announced that it has raised $10 million from Prevail Partners, which will help the company perform trials for the FDA with hopes to market its Notura eye mask in the US.

PolyPhotonix's Noctura 400 is a sleep mask that uses green OLED lighting panels for a non-invasive treatment for diabetic eye disease (DED). which helps patients with Diabetic Retinopathy. Pioneer supplies the OLED panels for PolyPhotonix.

The sleep mask emits a green light at a specific wavelength, so that the eye needs less oxygen, which, according to trials performed in the UK, help stabilize or even improve the condition. The sleep is used during the night, and it does not disturb the sleep patterns. This is a non-invasive treatment, a life long treatment that does not replace other treatments.

Tags:
Merck - Advancing Display, Advancing LifeMerck - Advancing Display, Advancing Life